# Ali Satvat

> Ali Satvat is a private equity investor at Kohlberg Kravis Roberts & Co. backing Health Care. See 17 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Kohlberg Kravis Roberts & Co.](https://shizune.co/investors/profile/kkr)
- Location: Menlo Park, United States
- Total investments: 17
- Last investment: Dec 2023
- Lead investor: 82%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ali-satvat-bb659a/

Ali Satvat is a private equity investor at Kohlberg Kravis Roberts & Co. in Menlo Park focused on Health Care and Biotechnology. Ali J. Satvat is based out of Menlo Park, California and is the Partner of Kohlberg Kravis Roberts & Co. Ali previously worked at Apax Partners as a principal. Ali J. Satvat attended the Wharton School of the University of Pennsylvania.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 53% |
| Biotechnology | 4 | 24% |
| Medical | 3 | 18% |
| Manufacturing | 3 | 18% |
| Medical Device | 3 | 18% |

27 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Private Equity | 5 | 29% |
| Series C | 3 | 18% |
| Series B | 2 | 12% |
| Series D | 2 | 12% |
| Funding Round | 2 | 12% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cortex | Cortex is creating an innovative, totally integrated, all-encompassing platform for assessing and treating AFib with precision, simplicity, and speed. The company has formed a proficient team comprising highly skilled and experienced engineers and clinical experts dedicated to introducing this innovative suite of technologies to the market. | $90M |  | Dec 07, 2023 |  |
| Cortex | Cortex is creating an innovative, totally integrated, all-encompassing platform for assessing and treating AFib with precision, simplicity, and speed. The company has formed a proficient team comprising highly skilled and experienced engineers and clinical experts dedicated to introducing this innovative suite of technologies to the market. | $90M | Private Equity | Dec 07, 2023 |  |
| Precipart | Precipart is a medical device company that offers motion control systems, ceramic injection molding, and micro manufacturing. |  | Private Equity | Oct 24, 2023 |  |
| Catalio Capital Management | Catalio Capital Management is a venture capital firm that invests in breakthrough biomedical technology companies. |  | Private Equity | Oct 17, 2023 |  |
| SkinSpirit Skincare Clinic and Spa | SkinSpirit has become one of the top destinations for aesthetic skin and body care in the country, with multiple locations in California and Washington. Co-founder and CEO, Lynn Heublein’s vision for SkinSpirit was to bring together the best of both worlds: cutting-edge products and services provided in a luxurious spa-like setting. We believe wehave succeeded in creating that place for you. We offer personal attention, sincere answers and a calm environment that will always keep you at ease. To complement our services, we curate the best in cosmeceutical products to provide our clients with proven home care regimens that get lasting results. |  | Private Equity | Oct 20, 2022 |  |
| Digital Diagnostics | Digital Diagnostics, formerly IDx, is a pioneering AI diagnostics company founded with a mission to transform the quality, accessibility, equity, and affordability of healthcare worldwide through the application of technology in the medical diagnosis and treatment process. Founded by Michael Abramoff, MD, PhD, a fellowship-trained retinaspecialist, neuroscientist, and computer engineer, Digital Diagnostics developed a patented biomarker-based approach to build an autonomous AI platform that makes clinical decisions without human intervention, removing the diagnostic burden of common diseases from specialists. Digital Diagnostics is paving the way for autonomous AI diagnosis to become the new standard of care, helping to democratize healthcare and close care gaps to improve patient outcomes. By working closely with patient advocacy groups, federal regulators, and other quality of care and ethics-focused stakeholders, Digital Diagnostics is working with the healthcare system to enable the continued adoption of autonomous AI. | $75M | Series B | Aug 23, 2022 |  |
| Clarify Health Solutions | Clarify Health enables health systems to deliver more satisfying and efficient care through a software and analytics platform that provides real-time insights and nudges to patients, family members, and clinicians. The solution optimizes episode of care workflows. Real-time tracking and machine learning analytics guide patients throughdynamically-updated care journeys. Patients and family members benefit from greater transparency, personalization, and engagement. Clinicians can focus on the highest need patients while the platform streamlines workflows and simplifies tasks. | $150M | Series D | Apr 05, 2022 |  |
| Sapphiros | Sapphiros invests in growth-stage diagnostic companies, focusing on technologies that prioritize innovation and patient-centric approaches. The company possesses a portfolio of capabilities and technologies encompassing innovative sample collection, next-generation diagnostics, computational biology, and printed electronics. These elementscontribute to the global accessibility of crucial diagnostic results for consumers. |  | Series A | Jul 21, 2021 |  |
| Clarify Health Solutions | Clarify Health enables health systems to deliver more satisfying and efficient care through a software and analytics platform that provides real-time insights and nudges to patients, family members, and clinicians. The solution optimizes episode of care workflows. Real-time tracking and machine learning analytics guide patients throughdynamically-updated care journeys. Patients and family members benefit from greater transparency, personalization, and engagement. Clinicians can focus on the highest need patients while the platform streamlines workflows and simplifies tasks. | $115M | Series C | Mar 16, 2021 |  |
| Paige | Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology,Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, minimize IT burden and costs while ensuring patient safety and data privacy. Paige’s products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products. | $125M | Series C | Jan 14, 2021 |  |

10 of 17 investments shown.

## Co-investors
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 2 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 2 deals together
- [Healthcare Venture Partners](https://shizune.co/investors/profile/healthcare-venture-partners) — VC Fund, 2 deals together
- [Hellman & Friedman](https://shizune.co/investors/profile/hellman-friedmann) — VC Fund, 2 deals together
- [Insight Partners](https://shizune.co/investors/profile/insight-partners) — VC Fund, 2 deals together
- [Johnson & Johnson Innovation](https://shizune.co/investors/profile/johnson-johnson-innovation-jjdc) — VC Fund, 2 deals together

## About Kohlberg Kravis Roberts & Co.

VC Fund · New York, United States

Kohlberg Kravis Roberts & Co. provides investment and asset management services through private equity, credit, infrastructure, real estate, and capital markets businesses that deploy capital into companies and projects across multiple industries. The company manages investment funds and strategic accounts that pursue acquisitions, buyouts,growth equity, credit solutions, and real assets on behalf of institutional investors and partners. It engages in financial activities that include underwriting, financing arrangements, and tailored investment strategies designed to support business growth and long-term value creation. Kohlberg Kravis Roberts & Co. also collaborates with institutional clients to structure investment vehicles that align with specific capital objectives and portfolio goals.

5 contacts available at Kohlberg Kravis Roberts & Co..

| Name | Title | Profile |
| --- | --- | --- |
| Ajay Candade | Director Private Equity | https://shizune.co/investors/profile/ajay-candade |
| Ali Satvat | Co-Head of Americas Private Equity Health Care | https://shizune.co/investors/profile/ali-satvat |
| Ashish Shastry | Co-Head of Private Equity for KKR Asia Pacific | https://shizune.co/investors/profile/ashish-shastry |
| Blaine MacDougald | Director & Co-head of Credit Research, Credit | https://shizune.co/investors/profile/blaine-macdougald |
| Brandon Freiman | Partner, Head of North American Infrastructure | https://shizune.co/investors/profile/brandon-freiman |

## Similar investors

### Similar stage
- [Foresight Group](https://shizune.co/investors/profile/foresight-group) — VC Fund
- [YFM Equity Partners](https://shizune.co/investors/profile/yfm-equity-partners) — VC Fund
- [Fondaction](https://shizune.co/investors/profile/fondaction) — VC Fund

## FAQ

### What does Ali Satvat invest in?

Ali Satvat invests primarily in Health Care, Biotechnology and Medical startups, most often at Private Equity and Series C stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ali Satvat last invest?

The most recent investment recorded for Ali Satvat closed in Dec 2023. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co